Top Markets
#1 Black Phoenix Black Phoenix +354.94%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +68.90%
#4 OpenEden OpenEden +67.50%
#5 Akedo Akedo +50.90%
#6 BasedHype BasedHype +26.45%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.93%
#9 Humanity Humanity +18.04%
#10 Ether.fi Ether.fi +17.36%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rank in Stocks #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Share Price
$0.00162013
Last synced: 2025-01-03
Market Cap
$156.25K
Change (1 day)
0.36%
Change (1 year)
0.00%
Country
SE
Trade Cyxone AB (publ) (CYXO)

Category

Healthcare
Revenue for Cyxone AB (publ) (CYXO)
Revenue in Jun 2024 TTM: $196.92K
According to Cyxone AB (publ) latest financial reports the company's current revenue (TTM) is $196.92K. In 2022 the company made a revenue of $613.68K an increase over the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cyxone AB (publ) from 2015 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $196.92K -61.41%
2023 $510.29K -16.85%
2022 $613.68K 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $2.85K 2,442.71%
2018 $111.93 0.00%
2017 0.00 -100.00%
2016 $2.31K -7.16%
2015 $2.49K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 6,410,780.38%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,057,634.10%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 5,134,366.39%
BE